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This study describes a CD4+ T helper (Th) cell subset
marked by coexpression of the cytokine interleukin
21 (IL-21) and the gut-homing chemokine receptor
CCR9. Although CCR9+ Th cells were observed in
healthy mice and humans, they were enriched in
the inflamed pancreas and salivary glands of NOD
mice and in the circulation of Sjo¨gren’s syndrome
patients. CCR9+ Th cells expressed large amounts
of IL-21, inducible T cell costimulator (ICOS), and
the transcription factors Bcl6 andMaf, and also sup-
ported antibody production from B cells, thereby
resembling T follicular B helper (Tfh) cells. However,
in contrast to Tfh cells, CCR9+ Th cells displayed
limited expression of CXCR5 and the targets of
CCR9+ Th cells were CD8+ T cells whose responsive-
ness to IL-21 was necessary for the development of
diabetes. Thus, CCR9+ Th cells are a subset of
IL-21-producing T helper cells that influence regional
specification of autoimmune diseases that affect
accessory organs of the digestive system.
INTRODUCTION
Accessory organs of the digestive system are connected to the
small intestine by excretory ducts and include the pancreas
and salivary glands, which are targets of the autoimmune
diseases type 1 diabetes (T1D) and Sjo¨gren’s syndrome, respec-
tively. T1D is a chronic autoimmune disease leading to the
destruction of the insulin-producing b cells in the islets of Lang-
erhans of the pancreas. In nonobese diabetic (NOD) mice, an
initially mild pancreatic infiltration progresses over a period of
2–3 months, culminating in the loss of insulin-producing islets
and clinical T1D (Bach and Mathis, 1997). However, islet inflam-
mation varies considerably and the infiltrate may exhibit features
of lymphoid neogenesis with ectopic germinal centers (GC)
(Astorri et al., 2010; Jansen et al., 1993; Kendall et al., 2007).
Studies collectively demonstrate that T cells of both the CD4+
and CD8+ lineages as well as B cells are necessary for the devel-602 Immunity 34, 602–615, April 22, 2011 ª2011 Elsevier Inc.opment of T1D in the NOD mouse (Serreze et al., 1996; Wicker
et al., 1994). However, their individual roles and interactions
remain poorly understood.
The autoimmune disease that develops in NOD mice also
targets other accessory organs of the digestive system, namely
the salivary glands and gallbladder. Similar to the pancreas, the
reduced function of the salivary glands is due to lymphocytic
infiltration, in which autoreactive T cells are thought to play
a major role (Goillot et al., 1991). Indications of gall bladder
involvement include diminished motility in NOD mice (Graewin
et al., 2004), and a congenic NOD strain has been shown to
spontaneously develop a fatal autoimmune biliary ductular
disease (Koarada et al., 2004).
Effector andmemory T cells can be classified based upon their
ability to traffic through peripheral tissues, a property controlled
by the expression of tissue-specific adhesion and chemoattrac-
tant receptors (Kunkel et al., 2003). CD4+ T helper (Th) cells
activated in intestinal lymph nodes selectively acquire respon-
siveness to the ligand (known as TECK or CCL25) for the G
protein-coupled chemokine receptor 9 (CCR9) (Papadakis
et al., 2000; Vicari et al., 1997; Wurbel et al., 2000) and express
high amounts of a4b7 integrin (Campbell and Butcher, 2002).
Lymphocytes infiltrating the islets in both human T1D and the
NOD mouse express a4b7-integrin, supporting a link between
T1D and the gastrointestinal immune system (Vaarala, 2002).
Furthermore, antibodies blocking either a4b7-integrin or its
ligand, the mucosal addressin cell adhesion molecule
(MadCAM-1), prevent diabetes in NOD mice (Ha¨nninen et al.,
1998; Phillips et al., 2005).
Cytokines produced by Th cells influence the maintenance of
the islet infiltrate and can contribute to b cell death either directly
or through their effects on immune cells. The cytokine interleukin
21 (IL-21), produced by several Th cell subsets, has a critical role
in both autoimmune diseases and inflammatory diseases of the
gastrointestinal mucosa (Monteleone et al., 2009). IL-21 is
thought to deliver a costimulatory signal that activates signaling
pathways affecting the proliferation, differentiation, and survival
of lymphocytes (Spolski and Leonard, 2008), but how IL-21
mediates its effect on autoimmune disease pathogenesis
remains an important unanswered question.
In this study, we describe a subset of IL-21-producing CCR9-
expressing CD4+ T cells with a Tfh cell-like phenotype that
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help to CD8+ T cells for the development of type 1 diabetes.
RESULTS
An Abundance of IL-21 from NOD CD4+ T Cells
Previous studies have shown that NOD mice exhibit increased
IL-21 mRNA expression relative to NODB6.Idd3 mice (King et al.,
2004; McGuire et al., 2009) that carry the gene encoding IL-21
within the Idd3 T1D susceptibility locus from C57BL/6 mice
(Lyons et al., 2000). IL-21 protein was similarly increased 2- to
3-fold from naive CD4+ T cells from NOD mice after polyclonal
activation in vitro (Figure 1A). ICOS is upregulated on CD4+
T cells after activation and provides a critical costimulatory signal
for T helper cell differentiation (Dong et al., 2001). Partitioning of
the CD44hi memory cells according to ICOS expression indi-
cated that although ICOS-expressing memory CD4+ T cells
were the major cellular source of IL-21 from both NOD and
NODB6.Idd3 cells, NOD ICOS+ memory CD4+ T cells produced
approximately 7-fold more IL-21 (Figure 1B).
IL-21 proteinwas also detected inmemory phenotype (CD44hi)
CD4+ T cells directly ex vivo by intracellular immunostaining, in
which the specificity of IL-21 detection was tested against
Il21/ NOD CD4+ T cells (Figures 1C and 1D). The results
demonstrated an age-related increase in both the fractions and
numbers of CD4+ T cells spontaneously producing IL-21 in the
pancreatic lymphnode (PLN) (Figures 1Eand1F), pancreatic infil-
trate (Figures 1G and 1H), spleen, mesenteric lymph nodes
(MLN), and blood (Figure S1 available online) of NOD mice
compared with NODB6.Idd3 mice. These findings indicated that
CD4+ Th cells from the lymphoid organs and inflamed tissues of
NOD mice produced an abundance of IL-21.
IL-21-Producing T Helper Cells in the Islet Lesion
Coexpress CCR9
Because of the close association of the pancreas and gut, we
analyzed the expression of the gut-homing molecules CCR9
and a4b7 integrin on IL-21-producing CD4+ T cells in the islet
infiltrate. Remarkably, the IL-21+ population in the islet lesion
coexpressed CCR9, with little evidence for a defined population
that expressed high amounts of either marker alone (Figure 1I).
The gut-homing characteristics of this population were sup-
ported by the observation that approximately 50% of cells also
expressed a4b7 integrin (Figure 1J). In addition, a small fraction
of cells were observed in the lamina propria of the small intestine
(Figure 1K). As noted previously, the chronic inflammation in
NOD mice is not restricted to the pancreas and includes the
salivary glands (Goillot et al., 1991). Therefore, it was of interest
to observe that approximately half of the CCR9-expressing CD4+
T cells in the salivary gland infiltrates also produced IL-21
(Figure 1L).
CCR9+ Th cells were enriched in the pancreatic infiltrates, sali-
vary gland infiltrates, and the PLN of NOD mice compared with
the tissues of congenic NODB6.Idd3 strain and C57BL/6 mice in
which infiltration into the pancreas and salivary glands was not
observed (Figure 1M). CCR9+ Th cells constituted a substantial
fraction of the total IL-21-producing CD4+ T cell population in
the pancreas and salivary gland infiltrates (Figure 1N) and
approximately 25% of IL-21-producing T cells in the MLN andlamina propria coexpressed CCR9 (data not shown). In addition,
CCR9+ Th cells were observed in the other accessory organs of
the digestive system, namely the gall bladder, biliary duct, and
liver of PBS-perfused NODmice (data not shown). CCR9 expres-
sion was not restricted to CD4+ T cells; it was observed on
approximately 15% of activated/memory phenotype CD8+
T cells and expressed highly on 10%of B cells in the islet infiltrate
(see also Figure S1) and was not dependent on IL-21 because
CCR9+ Th cells were observed in secondary lymphoid organs
of Il21/ and Il21r/ NOD mice (data not shown). Taken
together, these findings indicate that CCR9+ Th cells were
present throughout secondary lymphoid organs but were en-
riched in the inflamed accessory organs of the digestive system.
CCR9+ Th Cells Are Increased in the Blood of Patients
with Sjo¨gren’s Syndrome
To investigate the presence of CCR9-expressing T helper cells in
human autoimmune diseases that affect accessory organs of the
digestive system, we analyzed peripheral blood from a cohort of
patients with Sjo¨gren’s syndrome. Memory phenotype CCR9+
Th cells were detected in small numbers in both human tonsillar
tissues and peripheral blood (Figure 2A). By contrast, CCR9+ Th
cells were expanded in the circulation of most Sjo¨gren’s
syndrome patients (Figure 2B), and 9/15 Sjo¨gren’s syndrome
patients exhibited a 4- to 5-fold increase in memory phenotype
CCR9+ Th cells relative to controls (Figure 2C). The increased
fraction of CCR9+ Th cells in Sjo¨gren’s syndrome patients was
not simply due to an increase in the fraction of CD4+ T cells (Fig-
ure 2D) or memory phenotype CD4+ T cells (Figure 2E), which
were equivalent in the blood of patients and controls. However,
there were no significant differences (p > 0.05) in clinical or labo-
ratory parameters and no relationship between the proportion of
circulating CCR9+ Th cells and CXCR5+ Tfh cells in a subset of
patients in which both parameters were measured (data not
shown). These findings demonstrated that IL-21-producing
CCR9+ Th cells were observed in the peripheral blood of most
Sjo¨gren’s syndrome patients.
Expression of CCR9 Is Important but Not Necessary
for CCR9+ Th Cell Migration into the Pancreatic Islets
The expression of CCR9 suggested that IL-21-producing Th
cells in the islet lesions of NOD mice had originated from the
small intestinal mucosa and/or had the potential to home to
tissues that express its ligand, CCL25 (TECK) (Wurbel et al.,
2000). Previous studies have shown that CCL25 is
expressed at high amounts in the thymus and small intestine
(Wurbel et al., 2000). Immunoblot analyses also detected
CCL25 in isolated islet preparations from NOD mice and
confirmed the presence of CCL25 protein in the NOD intestine
(Figure 3A).
To determine whether CCR9 was a functional chemokine
receptor on CCR9+ Th cells, we performed a chemotaxis assay
in which migration of total lymphocytes, from PLN and pancreas
infiltrate, toward CCL25 was assessed. Lymphocytes observed
to migrate toward CCL25 in vitro (Figure 3B) were reduced by
CCL25 antibody blockade of CCR9:CCL25 interactions (Fig-
ure 3B). Flow cytometric analyses of the migrated populations
demonstrated enrichment for CCR9+ Th cells from both the PLN
(Figure 3C) and pancreas (Figure 3D). These observations wereImmunity 34, 602–615, April 22, 2011 ª2011 Elsevier Inc. 603
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Figure 1. Increased Production of IL-21 and Expansion of IL-21+CD4+ T Cells in NOD Mice
(A and B) Naive (CD44lo) CD4+ T cells from spleen and thymus (A) and memory (CD44hi), ICOS and ICOS+, CD4+ T cells from NOD and NODB6.Idd3 spleen (B),
cultured for 4 days with CD3 and CD28 mAb. IL-21 was measured by ELISA and data presented as means ± SEM; n = 6 mice per group from two experiments.
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Figure 2. Human CCR9+CD4+ T Cells Are
Expanded in Sjo¨gren’s Patients
(A) Representative dot plots of CCR9 expression
in human tonsil and peripheral blood.
(B–E) Flow cytometric analyses of blood from
healthy individuals (normal) and Sjo¨gren’s syn-
drome patients showing CCR9+ cells as a
percentage of CD4+ T cells (B) and CCR9+
CD45RA cells as a percentage of CD4+ T cells
(C); p values from nonparametric unpaired t tests.
Also shown are CD4+ T cells as a percentage of
peripheral blood mononuclear cells (PBMCs) (D)
and CD45RA+ cells as a percentage of CD4+
T cells (E), where n = 9–15.
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Tccr9 Cells Help CD8+ T Cells to Induce Diabetesborneout invivowhereblockadeofCCR9:CCL25 interactionswith
CCL25 Ab reduced the number of CFSE-labeled CCR9+ Th cells
recovered after 5 days from the pancreas and MLN, but not PLN
or spleen, of NOD recipients (Figure 3E). CCL25 antibody treat-
ment also reduced the number of endogenous CCR9+ Th cells
and CD8+ T cells in the islet lesion observed on day 7 of antibody
treatment (Figure 3F) and reduced the frequency of infiltrated islets(C and D) Representative dot plots of intracellular immunostaining for IL-21 in negative control Il21/ CD4+ T c
(E–H) IL-21 in NOD and NODB6.Idd3 CD4+ T cells in pancreatic lymph node, representative dot plot (E) and abso
in pancreas as representative dot plot (G) and absolute number of CD4+ T cells at ages shown (H), where n =
(I–L) Representative dot plots of CD4+ T cells. CCR9 and intracellular IL-21 (I) and IL-21 and a4b7 (J) on CD4+ T
plots of CCR9 and IL-21 in CD4+ T cells from small intestine lamina propria (K) and salivary gland (L).
(M and N) Percentage of CD4+ T cells that coexpress CCR9 and IL-21 (M), and percentage of IL-21+CD4+ T c
mice; n = 6–15 from four experiments; ND, not detected.
Immunity 34, 602–6(Figure 3G), and continued administration
inhibited the development of diabetes in
NODmice (Figure 3H).
Immunofluorescence of histological
sections of NOD pancreata identified
cells that coexpressed CD4 and CCR9
within the islet infiltrate (Figure 3I). Small
numbers of cells expressing both CD8
and CCR9 and B220 B cells expressing
CCR9 were also detected in the islet
lesion of NOD mice (Figure 3I). By
contrast, 1week after treatment, pancre-
atic islets of CCL25 Ab-treated NOD
mice frequently exhibited few infiltrating
lymphocytes (Figures 3I and 3G). There-
fore, CCR9:CCL25 interactions induced
the migration of CCR9+ Th cells, sup-
ported the pancreatic migration and/or
retention of CCR9+ Th cells, and were
important for diabetes development in
NOD mice.
CCR9+ Th Cells Are Distinct from
Th1, Th2, and Th17 Cells
CCR9+ Th cells in NOD mice had all the
hallmarks of a CD4+ Th effector memory
population, with high expression of
CD44 (Figure 1) and little CD62L orCCR7 expression (Table S1), but they were not NK T cells
because they failed tobind theCD1 tetrameraGalCer (FigureS2).
However, the cytokine profile of CCR9+ Th cells from the in-
flamed pancreas and PLN was largely restricted to IL-21
because, in contrast to CCR9 Th cells, CCR9+ Th cells were
observed to produce little, if any, IL-4, IL-17A, IFN-g, or TNF-a
after restimulation in vitro (Figure S2).ells in spleen (C) and pancreatic (D) lymph nodes.
lute number of CD4+ T cells at ages shown (F), and
16–22 mice per group from eight experiments.
cells from NOD pancreata and representative dot
ells that express CCR9 (N) from 9-week-old NOD
15, April 22, 2011 ª2011 Elsevier Inc. 605
Figure 3. A Role for CCR9:CCL25 Interactions in CCR9+ Th Cell Migration and the Development of Type 1 Diabetes
(A) Representative immunoblot showing CCL25 in NOD small intestine and pancreatic islets, compared to rCCL25, representative of three experiments.
(B) Chemotactic index calculated as the number of cells isolated from 11-week-old NOD pancreatic lymph nodes and pancreas that migrated across 3 mm
membrane toward rCCL25 (10 mg/ml), in the presence or absence of CCL25 Ab (4 mg/ml) over background migration.
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Immunity
Tccr9 Cells Help CD8+ T Cells to Induce DiabetesTranscription factors act asmaster controllers of cytokinegene
expression to establish lineage-specific transcriptional programs
during Th cell differentiation (Ivanov et al., 2006; Pai et al., 2004).
Analyses of the transcription factors expressed by CCR9+ Th
cells and CCR9 Th cells from the pancreas and PLN revealed
that the expression of Tbx21 (encoding T-bet) in both groups
was similar to the levels observed in Th1 cells differentiated
in vitro (Figure 4A). By contrast, the Th2 transcription factor
GATA-3 mRNA was lower in both CCR9+ Th cells and CCR9
Th cells relative to Th2 cells (Figure 4B). Despite the minimal
IFN-g production in CCR9+ Th cells, T-bet protein was detected
in both CCR9+ Th cells and CCR9 Th cells by immunoblot (Fig-
ure 4C; seealso FigureS2),whereas therewas little if anyGATA-3
protein detected in CCR9+ Th cells relative to CCR9 Th cells
(Figure 4C). In accordance with the lack of IL-17 production
from CCR9+ Th cells, the Th17 cell transcription factor Rorc (en-
coding ROR-gt) (Ivanov et al., 2006) was expressed at similar low
amounts in CCR9+ Th cells and CCR9 Th cells, relative to Th17
cells (Figure 4D). Thus, CCR9+ Th cells expressed transcription
factors typically associated with Tfh cells.
Pancreatic CCR9+ Th Cells Express High Amounts
of IL-21, Bcl-6, and Maf but Are Distinct from Tfh Cells
It was of interest to observe the Tfh cell transcription factorsMaf
(Bauquet et al., 2009) and Bcl6 (Yu et al., 2009; Johnston et al.,
2009; Nurieva et al., 2009) in abundance in CCR9+ Th cells
from the pancreas and PLN compared with both CCR9 Th cells
and Tfh cells (Figures 4E and 4F). In addition, the high expression
of both IL-21 and Bcl-6 was not restricted to murine CCR9+ Th
cells, as shown by the fact that CCR9+ Th cells from human
tonsillar tissue similarly expressed high amounts of both Bcl6
(Figure 4G) and IL-21 (Figure 4H) compared with memory pheno-
type CD4+ T cells that did not express CCR9.
Consistent with the presence of Tfh-like cells, histological
analyses of NOD pancreata and flow cytometric analyses of
the islet infiltrate revealed infrequent organized lymphoid aggre-
gates and PNA staining clusters (GC) with a small percentage of
GC B cells in nonimmunized NOD mice housed under SPF
conditions (Figure S3). However, further examination identified
markers that distinguished CCR9+ Th cells in the pancreatic
lesion from Tfh cells (King et al., 2008). For instance, the expres-
sion of the signaling lymphocyte activation molecule (SLAM)-
associated protein, SAP, was reduced compared with Tfh cells
(Figure 4I), and relatively few CCR9+ Th cells or CCR9 Th cells
in unmanipulated NOD mice expressed the B follicle homing
marker CXCR5 (Figure 4J). By contrast, in the Peyer’s patches
and salivary glands of NOD mice, approximately 30% and
15% of CD4+CD44hi T cells, respectively, coexpressed CCR9(C and D) Representative dot plots of the total and migrated CD4+ T cells (CCR9/I
from two experiments.
(E and F) 10- to 13-week-old NOD mice treated with CCL25 Ab, or control Ab, 2
(E) CFSE-labeled pancreas and pancreatic lymph nodes sorted CCR9+ Th cells r
(PLN), and pancreas, on day 5.
(F) Numbers of endogenous CCR9+ Th cells and CD8+ T cells on day 7. n = 4 fro
(G) Insulitis index day 14, n = 4–6 from two experiments.
(H) Cumulative incidence of diabetes, n = 8–11.
(I) Representative sections of pancreata on day 14, stained for insulin (blue) and
Arrows indicate the position of CCR9 costaining on immune cells. Scale bars repand CXCR5, indicating the presence of CCR9-expressing
Tfh-phenotype cells at these sites (Figure 4J). In support of
this, SAP expression was also more highly expressed in
CXCR5+CCR9+ Th cells than CXCR5CCR9+ Th cells from the
Peyer’s patches (Figure S2). However, in contrast to Tfh cells,
the coinhibitory molecules PD-1 and BTLA were not consistently
expressed on either CCR9+ or CCR9 Th cells (Figures 4K and
4L). The costimulatory molecule ICOS, in turn, was more highly
expressed on CCR9+ Th cells than CCR9 Th cells (Figure 4L).
Thus, pancreatic CCR9+ Th cells were distinguished from Tfh
cells by differential expression of CXCR5, PD-1, and SAP.
CCR9+ Th Cells Resist Upregulation of CXCR5 In Vitro
Recent studies have highlighted the plasticity of T helper
cell subsets (Wei et al., 2009). Therefore, we questioned
whether, given appropriate signals, CCR9 could be upregulated
on Tfh cells and whether CXCR5 could be upregulated on
CXCR5CCR9+ Th cells. Culture of Tfh cells purified from immu-
nized NOD mice and naive CD4+ T cells with dendritic cells puri-
fied from the MLN (Elgueta et al., 2008) demonstrated that Tfh
cells were relatively refractory to CCR9 upregulation in vitro (Fig-
ure 4M). Likewise, CCR9+ Th cells from the PLN and pancreas
cultured under Tfh cell-inducing conditions (Nurieva et al.,
2008) upregulated CXCR5 poorly in comparison to both CCR9
Th cells and naive CD4+ T cells (Figure 4N). Furthermore, expres-
sion of CXCR5 and PD-1 were increased on CCR9 Th cells but
not CCR9+ Th cells in vivo after immunization with a polyvalent
antigen (Figure S3).
Reciprocal Relationship between CCR9+ Th Cells
and B Cells
B cells have been shown to be important for the development of
T1D in the NOD mouse (Serreze et al., 1996), and the increased
expression of ICOS and IL-21 by CCR9+ Th cells indicated the
potential for superior interaction with B cells. Similar to CCR9-
expressing CD4+ T cells from human blood (Papadakis et al.,
2003), pancreatic CCR9+ Th cells supported antibody produc-
tion from B cells. However, CCR9+ Th cells and CD4+ ICOShi
(CCR9) T cells from the spleen equally supported the produc-
tion of IgM, total IgG, and IgG1 and IgG2c isotypes from B cells
purified from the pancreas and spleen in vitro (Figure 5A). Both
Th cell populations were more effective than naive CD4+
T cells, but the amounts of antibody were modest compared
with B cells stimulated with CD40 ligand (Figure 5A; Figure S4).
Because any interaction of CCR9+ Th cells and B cells was
likely to have reciprocal effects, IL-21 expression was measured
in NOD mice that had been made genetically deficient in B cells
(Ighm/). Both IL-21 mRNA and IL-21 protein production wereL-21) from pancreatic lymph node cells (C) and pancreatic infiltrate (D); n = 4–5,
0 mg, i.v. 3 times per week. n = 4 from two experiments.
ecovered from spleen, mesenteric lymph node (MLN), pancreatic lymph node
m two experiments.
CCR9 (red). Row 1 CD4 (green), row 2 CD8 (green), and row 3 B220 (green).
resent 20 mm.
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Figure 4. Transcription Factor and Surface Marker Characterization of CCR9+ Th Cells
Real-time PCR analysis and immunoblot of transcription factors and FACS analyses of cell surface markers from CCR9+CD44hiCD4+ T cells, sorted from NOD
pancreas and pancreatic lymph nodes; sorted naive CD44loCD4+ T cells and CCR9CD44hiCD4+ T cells from the pancreas and pancreatic lymph nodes; Th1,
Th2, and Th17 polarized lymphocytes; and CXCR5+Pd1+CD44hiCD4+ (Tfh) cells from the spleen of day 7 SRBC immunized NOD mice.
(A and B) Real-time PCR analysis of Tbx21 (A) and Gata3 (B).
(C) T-bet and GATA-3 protein expression after 3 days in vitro stimulation with CD3 mAb and CD28 mAb (Th0), representative of three experiments.
(D–F) Real-time PCR analysis of Rorc (D), Maf (E), and Bcl6 (F).
(G and H) Real-time PCR of Bcl6 (G) and Il21 (H) in human tonsillar CCR9+CD45RACD4+ T cells, from two experiments.
(I) Real-time PCR analysis of sh2d1a (SAP) expression. Murine RT-PCR data shown as mean ± SEM, where n = 4–8 from three experiments.
(J and K) Quantification of CXCR5 (J) and PD-1 (K) on CCR9+ and CCR9, CD44hiCD4+ T cells and Tfh cells by flow cytometry.
(L) Expression of ICOS, BTLA, and SLAM on pancreatic CD44hiCD4+ T cells; n = 3–6 from two experiments.
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Tccr9 Cells Help CD8+ T Cells to Induce Diabetessubstantially reduced in Ighm/ NOD mice compared with WT
NOD mice (Figure S4), which may reflect the previous finding
from our laboratory and others that ICOS:ICOSL interactions
are important for optimal production of IL-21 or for the differen-
tiation of IL-21-producing Th cells (Bauquet et al., 2009; Vogel-
zang et al., 2008).
Flow cytometric analyses of lymphocytes from the PLN and
pancreas lesion confirmed a physical association between
CD4+ T cells and B cells, known as conjugates (Reinhardt
et al., 2009). CCR9+ Th cells from the PLN (Figure 5B) and
pancreas (Figure 5C) were detected in conjugates with B cells,
and chemical disruption of the conjugates ex vivo confirmed
CCR9 expression on the bound CD4+ T cells (Figure 5D).
CCR9+ Th cells from NOD mice facilitated this interaction as
shown by the fact that adoptively transferred NOD CCR9+ Th
cells formed conjugates with NODB6.Idd3 B cells in pancreatic
infiltrates (Figure 5E).
During the analyses, we noted with great interest a marked
reduction in the percentage of CD8+ T cells in the pancreas of
NODB6.Idd3 mice compared with NOD mice (Figure 5F). Transfer
of CCR9+ Th cells from NOD mice also increased the fraction of
CD8+ T cells in the pancreas of NODB6.Idd3 recipients (Figure 5F).
This effect was dependent on CCR9+ Th cells as shown by the
fact that donor CCR9 Th cells had no effect on the percentages
of either T:B conjugates or CD8+ T cells in NODB6.Idd3 recipients
(Figures 5E and 5F). Taken together, these findings indicated
that CCR9 Th cells interacted with B cells for optimal production
of IL-21 and influenced the recruitment or maintenance of
lymphocytes in the islet lesion.
CD8+ T Cells Are the Downstream Targets for IL-21
in T1D
Despite the important role of IL-21 in T1D, the mechanism by
which IL-21 imparts its effects remains unknown. Previous
studies have shown that both CD4+ Th cells and CD8+ T cells
are required for the adoptive transfer of T1D into immunodefi-
cient NOD-SCID hosts (Christianson et al., 1993). We took
advantage of this system to determine IL-21’s influence on
T cells by comparing the capacity of IL-21-producing versus
IL-21-deficient CD4+ Th cells to help diabetogenic CD8+
T cells. The importance of IL-21 production from Th cells was
demonstrated by the inability of IL-21-deficient Th cells to assist
CD8+ T cells to induce diabetes (Figure 6A). Furthermore, the
transfer of diabetes by CD8+ T cells or CD4+ Th cells from
NOD mice made genetically deficient in IL-21R (when mixed
with WT Th and CD8+ T cells) revealed that IL-21 competence
by CD8+ T cells was critical for diabetes development
(Figure 6B).
IL-21 Promotes Expansion and Survival of CD8+ T Cells
The requirement for IL-21 receptiveness by CD8+ T cells promp-
ted us to examine IL-21’s role. Exploiting the available IL-21 in
Il21r/ NOD mice, polyclonal, CFSE-labeled, CD8+ T cells puri-(M) Mean fluorescent intensity (MFI) of CCR9 expression from naive (CD44lo) and
cells and SRBC. Data shown as MFI increase above stimulation in the absence
(N)Mean fluorescent intensity of CXCR5 expression from naive (CD44lo), CCR9 a
conditions. Data shown as MFI increase above stimulation in the absence of Tfhfied fromNODmice were transferred into NOD and Il21r/NOD
recipients. A small number of transferred, CFSE-labeled,
memory phenotype CD8+ T cells spontaneously proliferated in
NOD recipients (Figure 6C). Remarkably, extensive proliferation
was observed in Il21r/ NOD recipients (Figure 6C). This
spontaneous expansion of CD8+ T cells was dependent upon
IL-21 in the recipient mice because WT NOD CD8+ T cells failed
to proliferate spontaneously in NOD recipients made genetically
deficient in both IL-21 and IL-21R (Il21/Il21r/ NOD mice)
(Figure 6C). The increased IL-21-dependent proliferation was
consistent with an increased recovery of CD8+ T cells from the
spleen, MLN, and PLN of recipient mice (Figure 6D) and was
observed for both CD44hi memory phenotype and CD44lo naive
donor CD8+ T cells (Figure 6E). Interestingly, despite the broad
influence of IL-21 on the proliferation of CD8+ T cells, the
increased recovery was attributed to the memory population
(Figure 6F).
IL-21:IL-21R signaling on CD8+ T cells had improved their
recovery, suggesting that IL-21 supported the survival of CD8+
T cells. In support of this notion, IL-21 induced an increased
number of total CD8+ T cells that expressed the prosurvival
molecule Bcl-2 (Figure 6G), as well as a greater number of Bcl-
2-expressing donor memory phenotype than donor naive CD8+
T cells that had undergone cell division (Figure 6H). Taken
together, these studies indicate that Th cells provide IL-21 to
CD8+ T cells, which facilitates CD8+ T cell expansion and the
subsequent destruction of islet b cells.CCR9+ ThCells Provide IL-21-Dependent Help to CD8+ T
Cells to Induce Diabetes
To test directly whether CCR9+ Th cells could help CD8+ T cells
to cause diabetes, we transferred CCR9+ Th cells purified from
the pancreas and PLN combined with WT CD8+ T cells into
Il21r/ NOD recipients. Diabetes-resistant Il21r/ NOD recip-
ient mice were irradiated to provide room for the expansion of
the small number of donor cells (Figure S4). Two weeks after
transfer, Il21r/ recipients of CCR9+ Th cells plus CD8+ T cells
were exhibiting difficulty in regulating blood glucose after the
administration of a bolus of glucose during a glucose tolerance
test (Figure 7A). By contrast, all other groups, including Il21r/
recipients of CCR9+ Th cells plus CD8+ T cells that had received
IL-21RFc chimera, CCR9 Th cells plus CD8+ T cells, CD8+
T cells alone, or control Il21r/ NOD mice that had received
only PBS regulated blood glucose levels normally after an initial,
expected, spike (Figure 7A).
Histological analyses of the pancreata of Il21r/ NOD recipi-
ents of CCR9+ Th cells plus CD8+ T cells detected the presence
of both CD8- and CCR9/CD4-expressing cells in and around the
insulin-immunostained islets (Figure 7B). These mice developed
rapid insulitis compared with recipients of CCR9 Th cells
combined with WT CD8+ T cells (p < 0.001), as well as CCR9+
Th cells alone, WT CD8+ T cells alone, and irradiated Il21r/
NOD mice that did not receive cells, which were all free ofTfh cells after in vitro stimulation with mesenteric lymph node-derived dendritic
of dendritic cells (no-DC cultures); n = 3, representative of two experiments.
nd CCR9+, CD44hiCD4+ T cells after in vitro stimulation under Tfh cell-polarizing
cell-polarizing conditions (Th0); n = 3–4, representative of two experiments.
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Figure 5. CCR9+CD4+ T Cells Interact with B Cells and Influence
CD8+ T Cells
(A) IgM, IgG, IgG1, and IgG2c production from sorted splenic or pancreatic
B220+ B cells cultured with plate-bound CD3mAb and soluble CD28 mAb and
equal numbers of splenic naive CD44loCD4+ T cells (naive), CCR9ICOS+
CD44hiCD4+ T cells (CCR9) and pancreatic CCR9+CD44hiCD4+ T cells
(CCR9+), or CD40 mAb. Antibody isotypes measured in supernatant by ELISA
on day 4, data presented as mean ± SEM; n = 3–5 from two experiments.
(B and C) Representative flow cytometric plots of CD4 and B220, and CCR9
expression, gated on CD4+ T cells from pancreatic lymph node (B) and
pancreas (C).
(D) Pancreatic lymph node CD4+ T cells as shown in (B) sorted on CD4+B220+
doublets, subsequently disrupted with EDTA containing buffer and immuno-
stained for CCR9. 53 105 CCR9+ and CCR9CD44hiCD4+ T cells sorted from
pancreatic lymph nodes and pancreas were transferred into NODB6.Idd3 mice.
(E and F) Pancreatic lymph nodes and pancreas were analyzed on day 16 for
CD4+B220+ doublets (E) and CD8+ T cells (F).
Data are shown as mean ± SEM; n = 3–6 from three experiments.
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submandibular salivary glands was observed only in the recipi-
ents of CCR9+ Th cells plus CD8+ T cells, complementing the
observations in the pancreas (Figure 7B).
Recipient mice treated with neutralizing IL-21RFc exhibited
relatively mild peri-insulitis, indicating that IL-21 production by
CCR9+ Th cells was critical for the observed islet inflammation
(Figure 7C). In accordance with increased islet infiltration,
approximately 70% of the Il21r/ NOD recipients of CCR9+ Th
cells combined with CD8+ T cells had developed rapid diabetes
within 8 weeks of transfer compared with 0% of Il21r/ NOD
recipients of CCR9 Th cells and WT CD8+ T cells or CCR9+
Th cells alone (Figure 7D). Neutralization of IL-21 with IL-21RFc
confirmed that the ability of CCR9+ Th cells to induce diabetes
was dependent upon IL-21 (Figure 7D). Thus, CCR9+ Th cells
have an enhanced potential to provide IL-21-mediated help to
CD8+ T cells for the transfer of diabetes.
DISCUSSION
Region-specific Th cell subsets, such as Th2 cells in the respira-
tory mucosa or the newly identified Th22 cells in the skin (Duhen
et al., 2009; Trifari et al., 2009), express their unique effector
functions during immune defense. In this study we have identi-
fied a Th cell subset based upon expression of the chemokine
receptor CCR9 that contributes to the regional specification of
organ-specific autoimmune diseases. CCR9+ Th cells consti-
tuted only a small fraction of CD4+ T cells in the lymphoid tissues
and circulation of healthy mice and humans but exhibited an
inappropriate accumulation in the autoimmune lesions of the
nonlymphoid accessory organs of the digestive system in NOD
mice and were abundant in the peripheral blood of most Sjo¨g-
ren’s syndrome patients.
Antigen specificity is a prerequisite for the accumulation of
T cells in the islet lesion (Lennon et al., 2009), but the site of
priming of diabetogenic T cells remains unknown. The finding
that CCR9 marked the IL-21-producing Th cell subset in islet
lesions, PLN, and mesenteric LN support the notion that dia-
betes-causing T cells are primed in the gut and the previous
finding that lymphocytes from gut-associated lymph nodes are
highly effective at inducing diabetes (Jaakkola et al., 2003). In
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Figure 6. IL-21 Supports Survival of CD8+ T Cells
(A and B) Cumulative incidence of diabetes in NOD-SCID recipients of (A) 53 106 WT NOD or Il21/ NOD CD4+ T cells combined with 53 106 WT CD8+ T cells,
n = 8 and (B) 53 106 CD4+ T cells and 53 106 CD8+ T cell from WT and Il21r/ NOD mice, CD4+ T cell and CD8+ T cell combined transfers as indicated; n = 6.
(C and D) Total CFSE-labeled NOD CD8+ T cells (10 3 106) recovered from WT NOD, Il21r/ NOD, and Il21/Il21r/ NOD mice shown as (C) representative
histograms of CFSE dilution and (D) numbers of recovered transferred CD8+ T cells.
(E and F) CFSE-labeled CD44hi and CD44loCD8+ T cells (2 3 106) recovered from WT NOD, Il21r/ NOD, and Il21/Il21r/ NOD mice shown as (E) repre-
sentative histograms of CFSE dilution and (F) numbers of recovered CD8+ T cells.
(G and H) Bcl2 expression of recovered CD8+ T cells as shown in (C) and (E), with isotype control reference (gray filled histogram). Data are shown on day 7 after
transfer; n = 3–8, representative of four experiments.
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Tccr9 Cells Help CD8+ T Cells to Induce Diabeteshealthy humans and mice, CCR9 is expressed predominately by
a subset of T cells that migrate selectively to the gut (Papadakis
et al., 2003) and local dendritic cells can imprint CCR9 onmature
T cells (Mora et al., 2003). CCR9+ T cells play a role in severalgastrointestinal tract inflammatory disorders (Koenecke and Fo¨r-
ster, 2009). However, the relatedness to the CCR9+ Th cells
described herein awaits confirmation. CCL25 is found in the
small intestine and thymus (Wurbel et al., 2000), and theImmunity 34, 602–615, April 22, 2011 ª2011 Elsevier Inc. 611
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Figure 7. IL-21 Is Critical for Diabetes Caused by
CCR9+ Th Cells
Il21r/ NOD mice received 5 3 105 CCR9+CD44hiCD4+
T cells or CCR9CD44hiCD4+ T cells either alone or
combined with CD8+ T cells, with or without IL-21RFc
10 mg/mouse every other day for 12 days.
(A and B) Two weeks after transfer, (A) glucose tolerance
tests were conducted at 30 and 60 min, with significant
difference (*) between CCR9+ + CD8+ T cells ± IL-21R/FC;
(B) pancreas and salivary glands were assessed by
immunofluorescence showing insulin (blue), CD8 (green),
and CCR9 (red) and immunohistochemistry, showing
insulin stained brown, with hematoxylin. Scale bars
represent 50 mm.
(C and D) Pancreata from Il21r/ NOD recipients were
scored for insulitis on day 14 (C) and incidence of diabetes
(D); n = 5 from three experiments.
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Tccr9 Cells Help CD8+ T Cells to Induce Diabetesdetection of CCL25 in the pancreas offered a plausible link
between CCR9+ Th cells, the intestine, and pancreas and that
pancreatic CCL25 may aid CCR9+ Th cell access to, or retention
in, the islet lesion. The ability of CCL25 blockade to reduce insu-612 Immunity 34, 602–615, April 22, 2011 ª2011 Elsevier Inc.litis and inhibit diabetes was of therapeutic
importance, but whether this reflected a singular
effect on CD4+ T cells remains unknown.
Phenotypic characterization indicated that
CCR9+ Th cells were neither Th1, Th2, nor
Th17 cells. Instead, they exhibited high amounts
of the Tfh cell transcription factor Bcl-6 and
a cytokine profile that was largely restricted to
IL-21, which is produced by Tfh cells, but under
strong epigenetic repression in both Th1 and
Th2 cell subsets (Wei et al., 2009). Bcl6
represses IL-4, IFN-g, and IL-17 expression
(but not IL-21 expression) during Tfh cell differ-
entiation (Kusam et al., 2003; Nurieva et al.,
2009; Yu et al., 2009), indicating that the high
expression of Bcl6 in CCR9+ Th cells could
explain their restricted cytokine profile.
A question that warrants closer inspection is
how CCR9+ Th cells acquire Tfh cell-like
features in unmanipulated mice housed under
SPF conditions. CCR9+ Th cells could be
distinguished from Tfh cells by their lack of
CXCR5, SAP, and reduced expression of
PD-1, but may be selectively recruited from
a CCR9+ precursor population in the follicular
environment of gut-associated lymphoid tissue.
In support of this, approximately 30% of
CCR9+ Th cells in the Peyer’s patches coex-
pressed CXCR5. However, pancreatic CCR9+
Th cells and Tfh cells resisted the in vitro
modulation of CXCR5 and CCR9, respectively.
Alternatively, CCR9+ Th cells may emerge from
the extrafollicular foci of lymphoid organs.
IL-21-producing extrafollicular Th (Tefh) cells,
which also lack expression of CXCR5, have
been described in the MLRlpr mouse model oflupus, where they regulate plasma cell differentiation (Odegard
et al., 2008).
Another possibility is that CCR9+ Th cells acquire their Tfh cell-
like characteristics in the islet lesion. Evidence for lymphoid
Immunity
Tccr9 Cells Help CD8+ T Cells to Induce Diabetesneogenesis in NOD mice, with ectopic GC in the pancreas, sali-
vary glands, and thyroid (Astorri et al., 2010; Jansen et al., 1993;
Kendall et al., 2007), indicates that a suitable environment may
exist for the maintenance and/or generation of a Tfh cell-like
transcriptome in CCR9+ Th cells. Indeed, the association of
CCR9+ Th cells and B cells in the islet lesion may have supported
CCR9+ Th cell differentiation and/or optimal production of IL-21
(Vogelzang et al., 2008). Dysregulated Tfh cells that provide help
to B cells have been associated with antibody-mediated autoim-
mune diseases (Linterman et al., 2009) and therefore are not typi-
cally associated with T1D. Yet NODmice carry a high expressing
IL-21 allele (McGuire et al., 2009), and both ICOS:ICOSL interac-
tions and IL-21:IL-21R interactions are necessary for the
development of T1D (Datta and Sarvetnick, 2008; Hawiger
et al., 2008; Spolski et al., 2008), highlighting the importance of
pathways that influence antigen receptor signals in autoimmune
disease.
Despite their close association with B cells, CCR9+ Th cells
were ultimately helpers of CD8+ T cells. The development of dia-
betes in immunodeficient hosts was dependent upon CD4+
T cells that produced IL-21 and CD8+ T cells that responded to
IL-21. Furthermore, the ability of CCR9+ Th cells combined
with CD8+ T cells to induce both salivary gland and islet infiltra-
tion as well as clinical diabetes in otherwise protected IL-21R-
deficient NOD mice was dependent upon IL-21. Recent studies
have demonstrated that IL-21 is critical for the maintenance of
CD8+ T cell responses during chronic infection (Søndergaard
and Skak, 2009). In this study, we demonstrate that IL-21 is simi-
larly important for the survival of diabetogenic CD8+ T cells in
nonlymphoid tissues. In contrast to the spontaneous or homeo-
static expansion of CD4+ T cells in NOD mice that was depen-
dent upon the unique NOD MHC class II molecule IAg7 alone
(D’Alise et al., 2008), IL-21was critical for the spontaneous prolif-
eration of CD8+ T cells that we have previously observed in NOD
mice (King et al., 2004). The inappropriate expansion and
survival of CD8+ T cells may have reflected responses to self
or environmental antigen that were facilitated by IL-21 either
alone or in conjunction with other endogenous cytokine growth
factors. In this manner, IL-21 formed a nexus between B cells,
CD4+ Th cells, and CD8+ T cells in the dynamic islet lesion and
united their collective roles in the pathogenesis of T1D.EXPERIMENTAL PROCEDURES
Mice
Female NOD Ltj and C7BL/6 mice were purchased from ARC (Perth, WA),
Ighm/ NOD mice from JAX (Serreze et al., 1996), and Congenic C57BL/6
(R450).NOD (NODB6.Idd3) mice from Taconic Farms. Il21/ mice created on
the 129 background (Lexicon and Deltagen) were backcrossed to NOD N10
by selecting for known NOD Idd loci (versus B6 regions) by PCR of genomic
DNA (speed congenics) (Serreze et al., 1996). Il21r/ mice (Ozaki et al.,
2002) were kindly provided by M. Smyth (Peter Mac Callum Cancer Centre,
Melbourne) and backcrossed to NOD N10 by speed congenics. Il21/ and
Il21r/ NOD mice underwent a genome scan of >600 markers including
detailed analyses of construct flanking regions (Australian Genome Research
Facility Ltd [AGRF]). Animals were housed under specific-pathogen-free
conditions and handled in accordance with the Garvan Institute of Medical
Research and St. Vincent’s Hospital Animal Experimentation and Ethics
Committee, which comply with the Australian code of practice for the care
and use of animals for scientific purposes. Blood glucose values (BGV) were
determined with Accu-chek Advantage blood glucose strips (Roche).Human Samples
Human tonsils were obtained from routine tonsillectomy at the St Vincent’s
Hospital (Darlinghurst, NSW, Australia). PB buffy coats were obtained from
the Australian Red Cross Blood Service. Blood samples were collected from
15 patients with Sjo¨gren’s syndrome recruited via immunology clinics at West-
mead Hospital, Sydney. All patients met accepted diagnostic criteria for this
condition (Vitali et al., 2002). Clinical and laboratory data were collected on
all patients; clinical data included the presence of symptomatic dry eyes,
mouth, skin, or vagina; gastrointestinal, renal, and respiratory symptoms; lach-
rymal or parotid swelling; Schirmer’s test result; Raynaud’s; presence of other
autoimmune diseases; recurrent oral candidiasis; the state of dentition; and
the use of medication. Laboratory data included the results of testing for anti-
nuclear antibodies, antibodies to extractable nuclear antigens, cryoglobulins,
hypergammaglobulinaemia, paraproteinaemia, rheumatoid factor, and
anemia. Institutional Human Research Ethics Committees approved all
studies.
Flow Cytometric Analyses
Isolation of lymphocytes from the pancreas and salivary gland were per-
formed as follows. Mice were euthanized by i.p. injection of ketamine and
perfused with ice-cold PBS for 10 min and isolated as described (Faveeuw
et al., 1995). After ex vivo staining of surface markers (Supplemental Exper-
imental Procedures), intracellular immunostaining (BD Biosciences) was
performed with biotin-labeled IL-21RFc (R&D Systems) as described (Suto
et al., 2008). Cytokines were detected ex vivo or after stimulation with
CD3 (2.5 mg/ml) and CD28 (2.5 mg/ml) mAb in culture medium containing
monensin (GolgiStop 1 ml/ml, BD Biosciences) at 37C for 4 hr. For analysis
of CD4+ T cell conjugates, EDTA was omitted from sample preparation
buffers. Sorted CD4+B220+ conjugates were dissociated with 2 mM EDTA
and vigorous vortexing, as previously described (Reinhardt et al., 2009).
Data were collected on a Canto flow cytometer (BD Biosciences) and
analyzed with FlowJo software (Tree Star, Inc.).
Immunohistochemistry
Serial sections of paraffin-embedded sections of pancreata were stained for
insulin (DakoCytomation) and glucagon (Chemicon) or PNA (Sigma). For
immunofluorescence, histological sections (5 mM) of frozen pancreata were
examined with a Leica laser scanning confocal microscope (Leica Microsys-
tems, Wetzlar, Germany), DM IRE2 TCS SP2 AOBS, with 203/0.70 (HCX PL
APO) and 633/1.40 (HCX PL APO) objectives. Excitation of fluorchromes
was via 488 nm (Ar), 543 nm (HeNe), or 633 nm (HeNe) lasers and emission
was recorded at 510–560 nm, 565–620 nm, or 650–720 nm. Images were
average projections of three optical sections and processed with the Leica
confocal software (Leica Microsystems, Wetzlar, Germany), ImageJ (http://
rsbweb.nih.gov/ij/), and Adobe Photoshop CS3 (San Jose´, CA). The anti-
bodies used for immunofluorescence were CCR9 (MAB.2435, Abnova),
CD4 (RM4-4, eBioscience), CD8 (53-6.7, eBioscience), and B220 (RA3-
6B2, eBioscience).
Chemotaxis Assay
Migration of lymphocytes from pancreatic lymph nodes and pancreatic infil-
trate toward rCCL25 was assessed with Transwell tissue culture inserts with
a 3 mM pore size polycarbonate filter (Millipore). Lymphocytes were resus-
pended at 1 3 107 cells/ml in RPMI 1640 medium supplemented with 0.5%
BSA, and 75 ml aliquots were loaded into the upper inserts. Buffer with or
without rCCL25 (10 mg/ml) (R&D Systems), with or without CCL25 Ab (4 mg/
ml) (R&D Systems), prepared in the same medium, were placed in the lower
wells. Chambers were incubated for 2 hr, and cell migration was quantified
by counting the number of cells acquired by flow cytometry in an equivalent
time period.
In Vivo Antibody Treatments
Mice received 50 mg/mouse total recombinant mouse IL-21RFc chimera
administered intravenously every other day for 12 days. IL-21RFc chimera
wasmade in house as previously described (Herber et al., 2007) and described
in Supplemental Experimental Procedures. For diabetes incidence, 20 mg of
CCL25 Ab (89818 R&D Systems) or rat IgG2b isotype control antibody (A95-
1; PharMingen) per mouse was given intravenously three times per week.Immunity 34, 602–615, April 22, 2011 ª2011 Elsevier Inc. 613
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p values between data sets were determined by two-tailed Student’s t test
assuming equal variance. Human data were compared with a nonparametric
t test. Data are reported as the mean ± SEM, along with the calculated
p values. The frequency of diabetes was compared between treatment groups
with the Kaplan-Meier log-rank test with Prism software (Graphpad).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
(RNA and qRT-PCR, CFSE proliferation, immunoblot, B cell help assay, and
sublethal irradiation), four figures, and one table and can be found with this
article online at doi:10.1016/j.immuni.2011.01.021.
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